Abstract
Pathological cardiac hypertrophy and cardiac fibrosis are remodeling events that result in mechanical stiffness and pathophysiological changes in the myocardium. Both humans and animal models display a sexual dimorphism where females are more protected from pathological remodeling. Fibroblast growth factor 2 (FGF2) mediates cardiac hypertrophy, cardiac fibrosis, and protection against cardiac injury, and is made in high molecular weight and low molecular weight isoforms (Hi FGF2 and Lo FGF2, respectively). Although some light has been shed on isoform-specific functions in cardiac pathophysiology, their roles in pathologic cardiac remodeling have yet to be determined. We tested the hypothesis that Lo FGF2 and Hi FGF2 modulate pathological cardiac remodeling in an isoform-specific manner. Young adult male and female mice between 8 and 12 weeks of age of mixed background that were deficient in either Hi FGF2 or Lo FGF2 (Hi KO or Lo KO, respectively) were subjected to daily injections of isoproterenol (Iso) for 4 days after which their hearts were compared to wild-type cohorts. Post-Iso treatment, female Lo KO hearts do not exhibit significant differences in their hypertrophic and fibrotic response, whereas female Hi KO hearts present with a blunted hypertrophic response. In male animals, Lo KO hearts present with an exacerbated fibrotic response and increased α-smooth muscle actin protein expression, whereas Hi KO hearts present with a blunted fibrotic response and increased atrial natriuretic factor protein expression Thus, in female hearts Hi FGF2 mediates cardiac hypertrophy, whereas in male hearts Lo FGF2 and Hi FGF2 display an antithetical role in cardiac fibrosis where Lo FGF2 is protective while Hi FGF2 is damaging. In conclusion, cardiac remodeling following catecholamine overactivation is modulated by FGF2 in isoform- and sex-specific manners.
Highlights
Pathologic cardiac remodeling is commonly associated with decompensated hypertrophy and fibrosis of the myocardium
Sympathetic overactivation is associated with other cardiac remodeling stimuli such as pressure overload (Siri 1988) and volume overload (Willenbrock et al 1997). This is the first report on the role of endogenous Fibroblast growth factor 2 (FGF2) isoforms in cardiac remolding, and our results demonstrate that following Iso treatment male Lo FGF2 knockout (Lo KO) hearts display an exacerbated fibrotic response and induction of a-smooth muscle actin (a-SMA), whereas male Hi FGF2 knockout (Hi KO) hearts exhibit attenuated fibrosis and induction of atrial natriuretic factor (ANF)
This study provides novel evidence on the interaction of sex and endogenous FGF2 isoforms as modulators of cardiac remodeling through hypertrophy and fibrosis
Summary
Pathologic cardiac remodeling is commonly associated with decompensated hypertrophy and fibrosis of the myocardium. Both of these events are considered detrimental for normal cardiac function and are common findings in heart disease which is the leading cause of death in the United States (Levy et al 1990). Low molecular weight FGF2 (Lo FGF2) is an 18 kDa protein translated from a conventional AUG start codon and its 155 amino acid sequence is common to all FGF2 isoforms (Ibrahimi et al 2004). The high molecular weight (Hi FGF2) isoforms (20.5 and 21 kDa) are produced by starting translation at CUG sites upstream and inframe of the AUG codon (Prats et al 1989)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
